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SouthAsianrenaltransplantrecipientshaveahigherincidenceofcardiovasculardiseasecomparedwithCaucasianrenaltransplant
recipients. We carried out a study to determine whether paraoxonase 1, a novel biomarker for cardiovascular risk, was decreased in
SouthAsiancompared withCaucasian renaltransplantrecipients.Subjects werematched twotooneonthebasisofageand sexfor
atotalof129subjects.Paraoxonase1wasmeasuredbymass,arylesteraseactivity,andtwo-substratephenotypeassay.Comparisons
were made by using a matched design. The frequency of PON1 QQ, QR and RR phenotype was 56%, 37%, and 7% for Caucasian
subjects versus 35%, 44%, and 21% for South Asian subjects (χ2 = 7.72, P = 0.02). PON1 mass and arylesterase activity were not
signiﬁcantlydiﬀerentbetweenSouthAsianandCaucasiansubjects.PON1masswassigniﬁcantlyassociatedwithPON1phenotype
(P = 0.0001), HDL cholesterol (P = 0.009), LDL cholesterol (P = 0.02), and diabetes status (P<0.05). Arylesterase activity was
only associated with HDL cholesterol (P = 0.003). Thus the frequency of the PON1 RR phenotype was higher and that of the QQ
phenotype was lower in South Asian versus Caucasian renal transplant recipients. However, ethnicity was not a signiﬁcant factor
as a determinant of PON1 mass or arylesterase activity, with or without analysis including PON1 phenotype. The two-substrate
method for determining PON1 phenotype may be of value for future studies of cardiovascular complications in renal transplant
recipients.
1.Introduction
Kidney transplant recipients (KTRs) are known to be at
increased risk for cardiovascular disease and by three years
after transplant about 40% of KTRs have experienced a
cardiovascular disease-related event [1]. The incidence of
disease is occurring in the context of best medical practice
for treatment of established cardiovascular risk factors. Thus
there is a need to identify novel risk factors with the objective
of improving treatment and reduction of the incidence of
cardiovascular disease.
End-stage renal disease, the precursor to KTR, is increas-
inginindividualsofSouthAsianethnicityrelativetosubjects
of Caucasian ethnicity [1]. There is a need to characterize
these subjects and determine whether novel risk factors for
cardiovascular disease are present in an ethnicity-dependent
manner. The current study was designed to compare two
novel risk factors, adiponectin and paraoxonase 1 (PON1),
as candidates for diﬀering risk between South Asian and
Caucasian KTR. We observed signiﬁcantly lower total and
high molecular weight adiponectin in South Asian KTR [2].
Stage 3 chronic renal disease, deﬁned as cystatin C-based2 Journal of Lipids
estimated glomerular ﬁltration rate (eGFR) less than 60, was
associated with lower PON1 mass in subjects with diabetes
[3].InthispaperwepresenttheanalysisforPON1andreport
that PON1 Gln192Arg (Q192R) phenotype is diﬀerent by
ethnicity.
2. Methods
2.1. Patient Selection. Subjects were recruited with age (±10
years) and gender matched in a 1:2, South Asian:Caucasian
ratio. Inclusion criteria were KTR of stated ethnicity with
stable renal function (less than 20% ﬂuctuation of creatinine
in the 2 months preceding recruitment), within 3 to 60
months of transplant, and able to provide informed consent.
Subjects were excluded if ethnicity was uncertain, if they
were multiorgan transplant recipients, if they had unstable
renal function, or if they were unable to understand the
consent process. Subjects who consented provided a blood
sample at the time of clinic visit in the nonfasting state. The
study was approved by the Human Research Ethics Board
of St. Michael’s Hospital. A total of 60 Caucasian males, 30
SouthAsianmales,26Caucasianfemales,and13SouthAsian
females were studied, slightly exceeding the study design
target sample of 120 subjects. A complete description of the
subjects can be found in Prasad et al. [2].
2.2. Measurements. Routine clinical laboratory measure-
ments were performed for standard blood clinical chemistry
analytes, including creatinine, glucose, and hemoglobin A1c.
Body mass index was determined from weight and height.
Clinical records were used for determination of the presence
of diabetes according to the 2008 Canadian Diabetes Asso-
ciation guidelines. Lipoproteins were analyzed by ultracen-
trifugation according to the Lipid Research Clinics protocol.
High-density lipoprotein cholesterol was determined by a
homogeneous assay on the Beckman LX-20 instrument
(Beckman, Mississauga, ON). Cystatin C, apolipoprotein
B, and apolipoprotein AI were measured using the Dade-
Behring BN Prospec (Dade-Behring, Mississauga, ON).
PON1 mass was measured on serum samples by Western
blot with a recombinant standard and calibrated with a
normal serum sample [4]. PON1 arylesterase activity was
measured using 3mM phenyl acetate to determine the
arylesterase activity and expressed in U/mL. PON1 pheno-
type was determined using the two-substrate assay of Richter
et al. [5] Data for the hydrolysis of 4-(chloromethyl)phenyl
acetate (CMPA) was plotted on the x-axis and data for
hydrolysis of phenyl acetate in the presence of 2M NaCl
(high salt conditions) was plotted on the y-axis. Data
was transformed using the arctangent of the ratio of
CMPA/arylesterase activity to derive the radians from the
origin. For convenience in presentation, these values were
converted to degrees. The activity for puriﬁed PON1 Q192
and PON1 R192 was used to conﬁrm identity of the QQ
and RR samples. The PON1 phenotypes were assigned as
follows: QQ, arctangent range from 11.8 to 17.08 degrees;
QR, arctangent range from 20.7 to 34.9 degrees; and RR,
arctangent range from 51.3 to 57.4 degrees.
2.3. Statistical Analyses. Analyses were carried using SAS 9.3.
Analysis of variance with the matched design was performed
using Proc Mixed. A P value < 0.05 was used for statistical
testing.
3. Results
Demographic data and biochemical data are summarized
in Table 1. Subjects were well matched by age at transplant
( 5 0v e r s u s5 2y e a r sf o rS o u t hA s i a nv e r s u sC a u c a s i a n )a n d
time after transplant (65 versus 71 months for South Asian
versus Caucasian). None of the established risk factors were
signiﬁcantly diﬀerent between South Asian and Caucasian
subjects by univariate analysis. PON1 mass and arylesterase
activity were similar between the two groups and had a
similar distribution as seen by comparison of the 25th and
75th percentiles.
Univariate Spearman correlation was determined for
PON1 mass and arylesterase activity by gender. Among
women,arylesteraseactivitycorrelatedwithPON1mass(r =
0.71, P<0.0001), HDL cholesterol (r = 0.45, P = 0.004),
and apoAI (r = 0.35, P = 0.03). Among men, arylesterase
activity correlated with PON1 mass (r = 0.78, P<0.0001),
but not with HDL cholesterol (r = 0.14, P = NS) and
weakly with apoAI (r = 0.21, P = 0.05). PON1 mass was not
signiﬁcantly correlated with either HDL cholesterol or apoAI
in either gender.
PON1phenotypewasdeterminedasdescribedbyRichter
et al. [5] using the two-substrate method. We observed clear
separation of the results into three phenotypes representing
the QQ, QR, and RR phenotypes (Figure 1). The frequency
of QQ, QR, and RR was signiﬁcantly diﬀerent (χ2 = 7.72, P =
0.02) between South Asian and Caucasian subjects with the
RR phenotype being 3 times more prevalent in South Asian
subjects (Table 2).
The determinants of PON1 mass were determined with
ethnicity and the covariates PON1 phenotype, lipoprotein
concentrations,diabetesstatus,andrenalstatusascovariates.
In spite of the diﬀerence in PON1 phenotype, ethnicity was
not a signiﬁcant determinant of PON1 mass. In contrast,
PON1phenotype,diabetesstatus,HDLcholesterol,andLDL
cholesterol were all signiﬁcantly associated with PON1 mass
(Table 3).
Nextthedeterminantsofserumarylesterasewerestudied
(Table 4). Again, ethnicity was not signiﬁcantly associ-
ated with arylesterase activity. Among the variables tested,
only HDL cholesterol was signiﬁcantly associated with
arylesterase activity (P = 0.003). When regression analysis
was performed including PON1 mass as an independent
variable, PON1 mass had a partial r2 of 0.67 (P<0.001),
PON1 phenotype had a partial r2 of 0.11 (P<0.001), and
HDL cholesterol had a partial r2 of 0.007 (P = 0.05). Thus
77% of the variation on arylesterase activity was accounted
for by PON1 mass and phenotype and less than 1% was
accounted for by HDL cholesterol.
Neither creatinine-based (MDRD) nor cystatin C-based
(Arnal-Dade) estimates of glomerular ﬁltration rate (eGFR)
showed a relationship with PON1 mass or arylesterase
activity (data not shown).Journal of Lipids 3
Table 1
Parameter
All patients
South Asian
(N = 43)
Caucasian
(N = 86) P-value
Age at transplant (years) 48 ±11 50 ±11 NS
A g ea ts t u d yv i s i t( y e a r s ) 5 0±10 52 ±11 NS
Gender (M/F) 30/13 60/26 NS
Time post transplant (months) 65 ±47 71 ±48 NS
BMI (kg/m2)2 6 .9 ±4.12 8 .0 ±6.0N S
Total cholesterol (mmol/L) 4.8 ±1.64 .4 ±1.1N S
HDL cholesterol (mmol/L) 1.1 ±0.41 .1 ±0.3N S
LDL cholesterol (mmol/L) 3.1 ±1.22 .7 ±0.90 . 0 7
Triglycerides (mmol/L) 1.8 ±0.91 .6 ±0.7N S
VLDL cholesterol 0.5 ±0.40 .5 ±0.3N S
VLDL triglycerides 1.3 ±0.81 .2 ±0.6N S
ApoAI (mg/L) 1.4 ±0.31 .4 ±0.3N S
ApoB (mg/L) 0.9 ±0.30 .8 ±0.2N S
eGFR by MDRD (mL/min/1.73m2)6 6 ±21 60 ±19 NS
Cystatin C (mg/L) 1.2 ±0.41 .2 ±0.3N S
eGFR by Cystatin C (mL/min/1.73m2)6 5 ±22 62 ±20 NS
C-reactive protein (mg/L) 4.5 ±7.96 .0 ±13 NS
PON1 (μg/mL) median (quartiles) 100 (84, 122) 105 (81.7, 127) NS
PON1 arylesterase (U/mL) median (quartiles) 79.5 (72.7, 90.4) 81.4 (72.2, 91.8) NS
PON1 CMPA activity (U/mL) median (quartiles) 19.4 (15.3, 26.8) 16.5 (13.6, 22.8) 0.08
PON1 arylesterase activity salt stimulated (U/mL)
median (quartiles) 45.4 (35.0, 54.7) 47.8 (37.3, 56.7) NS
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Figure 1: (a) Activity measured using phenyl acetate at high salt conditions versus CMPA. (b) Transformation of activities using arctangent
(x/y) ∗ 180/3.14 versus CMPA. This transformation converts x and y coordinates into the angle in degrees.
4. Discussion
PON1hasbeenextensively studiedasariskfactorforcardio-
vascular disease independent of lipoprotein concentrations
[6]. Diﬀerences in PON1 between subjects have been shown
to be due to genetic polymorphisms [7, 8], presence of
diabetes [9], presence of hepatic disease [10], and presence
of renal disease [3, 11–15]. The complexity of the genetic
polymorphism at the PON1 locus may confound studies of
PON1 and thus it has been suggested that determination
of the PON1 phenotype, mass, and activity be measured
[5, 16]. We report that the phenotypic prevalence of the QR4 Journal of Lipids
Table 2: Frequency of PON1 phenotypes by ethnicity.
Ethnicity PON1 QQ (n, %) PON1 QR (n, %) PON1 RR (n,% )
Caucasian 48 (55.8%) 32 (37.2%) 6 (7%)
South Asian 15 (34.9%) 19 (44.2%) 9 (20.9%)
Table 3: Mixed model ANOVA analysis with PON1 mass as the
dependent variable.
Variable P value
Ethnicity NS
PON1 phenotype 0.0001
Diabetes <0.05
HDL cholesterol 0.009
LDL cholesterol 0.02
Table 4: Mixed model ANOVA analysis with arylesterase activity as
the dependent variable.
Variable P value
Ethnicity NS
PON1 phenotype NS
Diabetes NS
HDL cholesterol 0.003
LDL cholesterol NS
and RR phenotype is higher in South Asian compared with
Caucasian KTR subjects. The frequency of the phenotypes
in Caucasians is similar to that reported for renal transplant
patients in Debrecen, Hungary [17, 18]. The frequency of
the phenotypes in South Asians is consistent with recently
published data on the frequency of the of Gln192Arg
polymorphism in North-West Indian Punjabis [6]. It is also
similar to that reported for patients with CAD or T2DM
from Hyderabad, India [19]. Interestingly, the frequency
of the RR was 11.7% in control subjects from Hyderabad,
similar to the frequency we observed for Caucasians.
In contrast to the diﬀerence in phenotype by ethnicity,
there was no diﬀerence in the mass or arylesterase activity of
PON1 by ethnicity in KTR. Further, there was a diﬀerence in
PON1 mass, but not arylesterase activity by diabetes status.
Analysis of indices of diabetes (glucose, hemoglobin A1c)
did not show signiﬁcant associations with PON1 mass or
arylesterase activity (data not shown). Post hoc analyses for
aninteractionbetweenethnicityanddiabetesstatuswerealso
negative. Thus, in this group of KTR subjects, diabetes was a
limited determinant of PON1 status. Similarly, an a priori
hypothesis was that renal function would be a determinant
of PON1. However, neither creatinine nor cystatin C-based
estimates of glomerular ﬁltration rate were associated with
PON1. This may be due to other factors in KTR being
primary determinants of PON1. It should also be noted that
the study design was to restrict subjects to a range of post
renal transplant from 3 to 60 months. Thus although most
of the subjects with diabetes had pre-transplant diabetes,
the duration of posttransplant factors was limited to the
relatively early time points. Most previous studies of non-
K T Rh a v eb e e no fs u b j e c t sw i t ha na v e r a g ed u r a t i o no f
d i a b e t e sg r e a t e rt h a n1 5y e a r s[ 20, 21]. Thus one explanation
for the absence of associations with diabetes and eGFR could
be the shorter duration after transplant in this study.
PON1 mass, but not arylesterase activity, has been
reported to be inversely correlated with mortality in patients
on dialysis [22]. In contrast, PON1 genotypes have not
been associated with increased cardiovascular risk in renal
transplant recipients [23]. Future studies will require mea-
surement of PON1 phenotype by enzymatic activity and
PON1 concentration in order to fully evaluate the predictive
value of PON1 as a cardiovascular risk factor in kidney
transplant recipients.
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